In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Qi Liu,Ye Tian,Yanyan Li,Wei Zhang,Wenxuan Cai,Yaju Liu,Yuefei Ren,Zhaoduan Liang,Peipei Zhou,Yajing Zhang,Yifeng Bao,Yi Li
DOI: https://doi.org/10.1136/jitc-2020-001748
IF: 12.469
2020-12-01
Journal for ImmunoTherapy of Cancer
Abstract:Background In patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), virus-specific cytotoxic T lymphocytes (CTLs) fail to eliminate HCC cells expressing HBV antigens. As the expression of viral antigen in HBV-associated HCC may decrease to allow tumor to escape immune attacks, we hypothesized that an HBV surface antigen (HBsAg)-specific affinity-improved-T-cell receptor (TCR) will enable T cells to target HCC more effectively than corresponding wild-type-TCR. We also postulated that TCR promiscuity can be exploited to efficiently capture HBV variants that can hinder CTL-based therapeutics. Methods We applied flexi-panning to isolate affinity-improved TCRs binding to a variant antigen, the human leukocyte antigen (HLA)-A*02:01-restricted nonapeptide HBs 371-379 -ILSPFLPLL, from libraries constructed with a TCR cloned using the decapeptide HBs 370-379 -SIVSPFIPLL. The potency and safety of the affinity-improved-TCR engineered T-cells (Ai-TCR-T) were verified with potentially cross-reactive human and HBV-variant peptides, tumor and normal cells, and xenograft mouse models. Results Ai-TCR-T cells retained cognate HBV antigen specificity and recognized a wide range of HBV genotypic variants with improved sensitivity and cytotoxicity. Cell infusions produced complete elimination of HCC without recurrence in the xenograft mouse models. Elevated accumulation of CD8 + Ai-TCR-T cells in tumors correlated with tumor shrinkage. Conclusion The in vitro and in vivo studies demonstrated that HBsAg-specific Ai-TCR-T cells had safety profiles similar to those of their wild-type counterparts and significantly enhanced potency. This study presents an approach to develop new therapeutic strategies for HBV-related HCC.
oncology,immunology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the immune escape problem in the treatment of hepatitis B virus (HBV) - related hepatocellular carcinoma (HCC). Specifically, the research focuses on enhancing the ability of T cells to recognize and kill HBV - related HCC cells by increasing the affinity of T - cell receptors (TCRs). In HBV - related HCC patients, virus - specific cytotoxic T lymphocytes (CTLs) are unable to effectively eliminate HCC cells expressing HBV antigens, and tumors may evade immune attacks by reducing the expression of viral antigens. The authors hypothesize that the use of high - affinity TCRs specific for HBV surface antigens (HBsAg) can target HCC cells more effectively. In addition, the authors also explore the possibility of using the polymorphism of TCRs to efficiently capture HBV variants that can hinder CTL - based treatments. The research methods include applying flexi - panning technology to isolate high - affinity TCRs that can bind to variant antigens from the constructed TCR library, and verifying the efficacy and safety of these high - affinity TCR - engineered T cells (Ai - TCR - T cells) through a series of experiments, including testing with potentially cross - reactive human and HBV variant peptides, tumor and normal cells, and xenograft mouse models. The research results show that Ai - TCR - T cells retain their specificity for HBV antigens and can recognize a wide range of HBV genotype variants with higher sensitivity and cytotoxicity. Cell infusion achieved complete elimination of HCC without recurrence in the xenograft mouse model, and the accumulation of CD8+ Ai - TCR - T cells in the tumor was associated with tumor shrinkage. The conclusion part points out that in - vitro and in - vivo studies show that HBsAg - specific Ai - TCR - T cells have safety comparable to that of wild - type TCRs and significantly enhanced efficacy, providing a new treatment strategy for HBV - related HCC.